Protective effects of tanshinone ⅡA on sepsis-induced multiple organ dysfunction: a literature review

doi:10.19852/j.cnki.jtcm.20230727.003

Abstract

Abstract:

TanshinoneⅡA (TanⅡA) is a noteworthy lipophilic diterpene compound derived from the dried roots of the Traditional Chinese Medicine Danshen (Radix Salviae Miltiorrhizae) that has various pharmacological properties, including anti-inflammatory, antibacterial, and antioxidative effects. Sepsis is a life-threatening organ dysfunction induced by a dysregulated host response to infection. Recently, increasing attention has been paid to sepsis-induced dysfunction of the intestine, car-diovascular system, lungs, kidneys, liver, and other organs. Experimental studies have shown that TanⅡA has therapeutic potential for sepsis-induced organ dysfunction owing to its anti-inflammatory, anti-apoptotic and regulatory effects on multiple signalling pathways. The purpose of this article is to evaluate the potential multiorgan protective effects of TanⅡA in sepsis.

Key words: tanshinoneⅡA, sepsis, multiple organ failure, review

WANG Lili, FENG Ju, ZHAN Daqian, WANG Junshuai, ZHOU Daixing. Protective effects of tanshinone ⅡA on sepsis-induced multiple organ dysfunction: a literature review[J]. Journal of Traditional Chinese Medicine, 2023, 43(5): 1040-1046.

Figures/Tables 1

References 82.

1.	Chen W, Chen GX. Danshen (Salvia Miltiorrhiza Bunge): a prospective healing sage for cardiovascular diseases. Curr Pharm Des 2017; 23: 5125-35.
2.	Fei YX, Wang SQ, Yang LJ, et al. Salvia miltiorrhiza Bunge (Danshen) extract attenuates permanent cerebral ischemia through inhibiting platelet activation in rats. J Ethnopharmacol 2017; 207: 57-66. DOI URL
3.	Hao DC, Ge GB, Xiao PG. Anticancer drug targets of Salvia Phytometabolites: chemistry, biology and omics. Curr Drug Targets 2018; 19: 1-20.
4.	Guo R, Li L, Su J, et al. Pharmacological activity and mechanism of tanshinone ⅡA in related diseases. Drug Des Devel Ther 2020; 14: 4735-48. DOI URL
5.	Ansari MA, Khan FB, Safdari HA, et al. Prospective therapeutic potential of tanshinone ⅡA: an updated overview. Pharmacol Res 2021; 164: 105364. DOI URL
6.	Fang J, Chen QY, He BZ, et al. Tanshinone ⅡA attenuates TNF-α induced PTX3 expression and monocyte adhesion to endothelial cells through the p38/NF-κB pathway. Food Chem Toxicol 2018; 121: 622-30. DOI URL
7.	Liu LJ, Gao HJ, Wen T, Gu T, Zhang S, Yuan ZY. Tanshinone IIA attenuates AOM/DSS-induced colorectal tumorigenesis in mice via inhibition of intestinal inflammation. Pharm Biol 2021; 59: 89-96. DOI PMID
8.	Ding B, Lin CH, Liu Q, et al. Tanshinone ⅡA attenuates neuroinflammation via inhibiting RAGE/NF-κB signaling pathway in vivo and in vitro. J Neuroinflammation 2020; 17: 302. DOI
9.	Tian XH, Wu JH. Tanshinone derivatives: a patent review (January 2006 - September 2012). Expert Opin Ther Pat 2013; 23: 19-29. DOI URL
10.	Hajj J, Blaine N, Salavaci J, Jacoby D. The "centrality of sepsis": a review on incidence, mortality, and cost of care. Healthcare 2018; 6: 90. DOI URL
11.	Prescott HC, Angus DC. Enhancing recovery from sepsis: a review. JAMA 2018; 319: 62-75. DOI PMID
12.	Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315: 801-10. DOI PMID
13.	Caraballo C, Jaimes F. Organ dysfunction in sepsis: an ominous trajectory from infection to death. Yale J Biol Med 2019; 92: 629-40. PMID
14.	Nedeva C, Menassa J, Puthalakath H. Sepsis: inflammation is a necessary evil. Front Cell Dev Biol 2019; 7: 108. DOI PMID
15.	Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008; 8: 776-87. DOI PMID
16.	Liu SF, Malik AB. NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 2006; 290: L622-45. DOI URL
17.	Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010; 38: S26-34. DOI URL
18.	Pool R, Gomez H, Kellum JA. Mechanisms of organ dysfunction in sepsis. Crit Care Clin 2018; 34: 63-80. DOI PMID
19.	Klingensmith NJ, Coopersmith CM. The gut as the motor of multiple organ dysfunction in critical illness. Crit Care Clin 2016; 32: 203-12. DOI PMID
20.	Otani S, Coopersmith CM. Gut integrity in critical illness. J Intensive Care 2019; 7: 17. DOI PMID
21.	Zhu W, Lu Q, Chen HW, Feng J, Wan L, Zhou DX. Protective effect of sodium tanshinone II A sulfonate on injury of small intestine in rats with sepsis and its mechanism. Chin J Integr Med 2012; 18: 496-501. DOI URL
22.	Liu SF, Malik AB. NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 2006; 290: L622-45. DOI URL
23.	Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-12. DOI PMID
24.	Zhu W, Lv Q, Chen HW, Wang ZH, Zhong Q. Protective effect and mechanism of sodium tanshinone ⅡA sulfonate on microcirculatory disturbance of small intestine in rats with sepsis. J Huazhong Univ Sci Technolg Med Sci 2011; 31: 441-45.
25.	Brown KA, Brain SD, Pearson JD, Edgeworth JD, Lewis SM, Treacher DF. Neutrophils in development of multiple organ failure in sepsis. Lancet 2006; 368: 157-69. DOI PMID
26.	Zhu W, Lu Q, Wan L, Feng J, Chen HW. Sodium tanshinone ⅡA sulfonate ameliorates microcirculatory disturbance of small intestine by attenuating the production of reactie oxygen species in rats with sepsis. Chin J Integr Med 2016; 22: 745-51. DOI URL
27.	Chen LY, Liu P, Feng X, Ma CH. Salidroside suppressing LPS-induced myocardial injury by inhibiting ROS-mediated PI3K/Akt/mTOR pathway in vitro and in vivo. J Cell Mol Med 2017; 21: 3178-89. DOI URL
28.	Cui WJ, Hu GX, Peng J, Mu L, Liu J, Qiao LJ. Quercetin exerted protective effects in a rat model of sepsis via inhibition of reactive oxygen species (ROS) and downregulation of high mobility group box 1 (HMGB1) protein expression. Med Sci Monit 2019; 25: 5795-800. DOI URL
29.	Yang XJ, Qian JX, Wei Y, et al. Tanshinone ⅡA sodium sulfonate attenuates LPS-induced intestinal injury in mice. Gastroenterol Res Pract 2018; 2018: 9867150.
30.	Merx MW, Weber C. Sepsis and the heart. Circulation 2007; 116: 793-802. PMID
31.	Joffre J, Hellman J, Ince C, Ait-Oufella H. Endothelial responses in sepsis. Am J Respir Crit Care Med 2020; 202: 361-70. DOI URL
32.	Meng ZJ, Wang C, Meng LT, Bao BH, Wu JH, Hu YQ. Sodium tanshinone IIA sulfonate attenuates cardiac dysfunction and improves survival of rats with cecal ligation and puncture-induced sepsis. Chin J Nat Med 2018; 16: 846-55.
33.	Ni JY, Zhao YX, Su J, et al. Toddalolactone protects lipopolysaccharide-induced sepsis and attenuates lipopolysaccharide-induced inflammatory response by modulating HMGB1-NF-κB translocation. Front Pharmacol 2020; 11: 109. DOI PMID
34.	Shi J, Xu H, Cavagnaro MJ, Li XM, Fang J. Blocking HMGB1/RAGE signaling by berberine alleviates A1 astrocyte and attenuates sepsis-associated encephalopathy. Front Pharmacol 2021; 12: 760186. DOI URL
35.	Li W, Li JH, Ashok M, et al. A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinfiammatory mediator, high mobility group box 1. J Immunol 2007; 178: 3856-64. DOI URL
36.	Huang LB, Zheng M, Zhou YD, et al. Tanshinone ⅡA attenuates cardiac dysfunction in endotoxin-induced septic mice via inhibition of NADPH oxidase 2-related signaling pathway. Int Immunopharmacol 2015; 28: 444-49. DOI URL
37.	Chen PP, An QY, Huang YX, Zhang MZ, Mao S. Prevention of endotoxin-induced cardiomyopathy using sodium tanshinone IIA sulfonate: involvement of augmented autophagy and NLRP3 inflammasome suppression. Eur J Pharmacol 2021; 909: 174438-38. DOI URL
38.	de Torre-Minguela C, Mesa Del Castillo P, Pelegrín P. The NLRP3 and pyrin inflammasomes: implications in the pathophysiology of autoinflammatory diseases. Front Immunol 2017; 8: 43. DOI PMID
39.	Franchi L, Muñoz-Planillo R, Núñez G. Sensing and reacting to microbes through the inflammasomes. Nat Immunol 2012; 13: 325-32. DOI PMID
40.	Chen SL, Tang CG, Ding HG, et al. Maf1 ameliorates sepsis-associated encephalopathy by suppressing the NF-B/NLRP3 inflammasome signaling pathway. Front Immunol 2020; 11: 594071. DOI URL
41.	Huang GW, Bao JW, Shao XH, et al. Inhibiting pannexin-1 alleviates sepsis-induced acute kidney injury via decreasing NLRP 3 inflammasome activation and cell apoptosis. Life Sci 2020; 254: 117791. DOI URL
42.	Chen HW, Feng J, Li SS. Protective effect of tanshinone ⅡA on myocardial apoptosis in rats with sepsis. Zhong Guo Yao Xue Za Zhi 2013; 48: 1459-63.
43.	Wang Z, Chen HW, Feng J. Involvement of cyclooxygenase-2 in mechanism of tanshinone IIA action in ameliorating cardiac myocyte apoptosis in rats with sepsis. Zhong Guo Yi Yuan Yao Xue Za Zhi 2015; 35: 1629-33.
44.	Lü DY, Luo MH, Yan JH, Yang XY, Luo SX. Protective Effect of sirtuin 3 on CLP-induced endothelial dysfunction of early sepsis by inhibiting NF-κB and NLRP3 signaling pathways. Inflammation 2021; 44: 1782-92. DOI PMID
45.	Xu SZ, Yan Y, Yan ZJ, et al. Septic serum mediates inflammatory injury in human umbilical vein endothelial cells via reactive oxygen species, mitogen activated protein kinases and nuclear factor-κB. Int J Mol Med 2021; 47: 267-75. DOI URL
46.	Cheng J, Chen TT, Li PY, et al. Sodium tanshinone ⅡA sulfonate prevents lipopolysaccharide-induced inflammation via suppressing nuclear factor-kappa B signaling pathway in human umbilical vein endothelial cells. Can J Physiol Pharmacol 2018; 96: 26-31. DOI URL
47.	Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 2016; 315: 788-800. DOI PMID
48.	Matthay MA, Zemans RL, Zimmerman GA, et al. Acute respiratory distress syndrome. Nat Rev Dis Primers 2019; 5: 18. DOI PMID
49.	Baradaran Rahimi V, Rakhshandeh H, Raucci F, et al. Anti-inflammatory and anti-oxidant activity of extract on LPS-induced rat lung injury. Molecules 2019; 24: 139. DOI URL
50.	Park I, Kim M, Choe K, et al. Neutrophils disturb pulmonary microcirculation in sepsis-induced acute lung injury. Eur Respir J 2019; 53: 1800786. DOI URL
51.	Shi J, Yu TX, Song K, et al. Dexmedetomidine ameliorates endotoxin-induced acute lung injury in vivo and in vitro by preserving mitochondrial dynamic equilibrium through the HIF-1a/HO-1 signaling pathway. Redox Biol 2021; 41: 101954. DOI URL
52.	Qian JX, Yang XJ, Wu J, et al. Effects of tanshinone IIA sodium sulfonate on LPS-induced acute lung injury in mice. Int J Clin Exp Med 2018; 11: 4605-13.
53.	Xu M, Dong MQ, Cao FL, et al. Tanshinone ⅡA reduces lethality and acute lung injury in LPS-treated mice by inhibition of PLA(2) activity. Eur J Pharmacol 2009; 607: 194-200. DOI URL
54.	Figueroa DJ, Breyer RM, Defoe SK, et al. Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes. Am J Respir Crit Care Med 2001; 163: 226-33. DOI URL
55.	Xu M, Cao FL, Liu LL, et al. Tanshinone ⅡA -induced attenuation of lung injury in endotoxemic mice is associated with reduction of hypoxia-inducible factor 1 alpha expression. Am J Respir Cell Mol Biol 2011; 45: 1028-35. DOI URL
56.	Zhao SL, Gao J, Li J, Wang SL, Yuan CC, Liu QH. PD-L1 regulates inflammation in LPS-induced lung epithelial cells and vascular endothelial cells by interacting with the HIF-1α signaling pathway. Inflammation 2021; 44: 1969-81. DOI PMID
57.	Ouyang HC, Tan Y, Li Q, et al. MicroRNA-208-5p regulates myocardial injury of sepsis mice via targeting SOCS2-mediated NF-κB/HIF-1α pathway. Int Immunopharmacol 2020; 81: 106204. DOI URL
58.	Xu M, Cao FL, Zhang YF, et al. Tanshinone ⅡA therapeutically reduces LPS-induced acute lung injury by inhibiting inflammation and apoptosis in mice. Acta Pharmacol Sin 2015; 36: 179-87. DOI
59.	Quan MX, Lv YN, Dai Y, et al. Tanshinone ⅡA protects against lipopolysaccharide-induced lung injury through targeting Sirt1. J Pharm Pharmacol 2019; 71: 1142-51. DOI URL
60.	Hoste EAJ, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med 2015; 41: 1411-23. DOI PMID
61.	Peerapornratana S, Manrique-Caballero CL, Gómez H, Kellum JA. Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment. Kidney Int 2019; 96: 1083-99. DOI PMID
62.	Bellomo R, Kellum JA, Ronco C, et al. Acute kidney injury in sepsis. Intensive Care Med 2017; 43: 816-28. DOI PMID
63.	Chen ZY, Huang JS, Xu YJ, Lin MY, Zou QM, Li CR. Tanshinone IIA alleviates acute liver and kidney injury in septic rats. Zhong Guo Mian Yi Xue Za Zhi 2020; 36: 1578-82.
64.	Gao HW, Liu X, Sun W, et al. Total tanshinones exhibits anti-inflammatory effects through blocking TLR4 dimerization via the MyD88 pathway. Cell Death Dis 2017; 8: e3004.
65.	Gao HW, Huang LT, Ding F, et al. Simultaneous purification of dihydrotanshinone, tanshinone I, cryptotanshinone, and tanshinone IIA from Salvia miltiorrhiza and their anti-inflammatory activities investigation. Sci Rep 2018; 8: 8460. DOI PMID
66.	Tauber SC, Djukic M, Gossner J, Eiffert H, Brück W, Nau R. Sepsis-associated encephalopathy and septic encephalitis: an update. Expert Rev Anti Infect Ther 2021; 19: 215-31. DOI URL
67.	Xiong CQ, Zhou HC, Wu J, Guo NZ. The Protective Effects and the involved mechanisms of tanshinone ⅡA on sepsis-induced brain damage in mice. Inflammation 2019; 42: 354-64. DOI
68.	Elibol-Can B, Kilic E, Yuruker S, Jakubowska-Dogru E. Investigation into the effects of prenatal alcohol exposure on postnatal spine development and expression of synaptophysin and PSD95 in rat hippocampus. Int J Dev Neurosci 2014; 33: 106-14. DOI PMID
69.	Nakamura R, Nishimura T, Ochiai T, Nakada S, Nagatani M, Ogasawara H. Availability of a microglia and macrophage marker, iba-1, for differential diagnosis of spontaneous malignant reticuloses from astrocytomas in rats. J Toxicol Pathol 2013; 26: 55-60. DOI PMID
70.	Iba T, Levy JH, Warkentin TE, Thachil J, van der Poll T, Levi M. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost 2019; 17: 1989-94. DOI PMID
71.	Iba T, Nisio MD, Levy JH, Kitamura N, Thachil J. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open 2017; 7: e017046. DOI URL
72.	Iba T, Levi M, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular coagulation. Semin Thromb Hemost 2020; 46: 89-95. DOI PMID
73.	Adelborg K, Larsen JB, Hvas AM. Disseminated intravascular coagulation: epidemiology, biomarkers, and management. Br J Haematol 2021; 192: 803-18. DOI URL
74.	Wu LC, Lin X, Sun H. Tanshinone ⅡA protects rabbits against LPS-induced disseminated intravascular coagulation (DIC). Acta Pharmacol Sin 2012; 33: 1254-59. DOI
75.	Schabbauer G, Tencati M, Pedersen B, Pawlinski R, Mackman N. PI3K-Akt pathway suppresses coagulation and inflammation in endotoxemic mice. Arterioscler Thromb Vasc Biol 2004; 24: 1963-69. DOI PMID
76.	Levi M. Disseminated intravascular coagulation: what's new? Crit Care Clin 2005; 21: 449-67. PMID
77.	Levi M ten Cate H. Disseminated intravascular coagulation-reply. N Engl J Med 1999; 341: 1938-38. DOI URL
78.	Xia ZY, He YF, Ni JD, et al. Effect of tanshinone ⅡA on platelet parameters, coagulation function and blood lactate in patients with sepsis. Acta Medica Mediterr 2020; 36: 2771-75.
79.	Strnad P, Tacke F, Koch A, Trautwein C. Liver-guardian, modifier and target of sepsis. Nat Rev Gastroenterol Hepatol 2017; 14: 55-66. DOI PMID
80.	Yan J, Li S, Li SL. The role of the liver in sepsis. Int Rev Immunol 2014; 33: 498-510. DOI PMID
81.	Gao M, Ou H, Jiang Y, et al. Tanshinone ⅡA attenuates sepsis-induced immunosuppression and improves survival rate in a mice peritonitis model. Biomed Pharmacother 2019; 112: 108609. DOI URL
82.	Ma SL, Wang X, Wang YJ, Zuo XR. Sodium tanshinone ⅡA sulfonate improves hemodynamic parameters, cytokine release, and multi-organ damage in endotoxemia rabbits. Med Sci Monit 2018; 24: 2975-82. DOI URL

[1]	LIU Tingting, LIU Tongou, LIU Mingfu. Effectiveness and safety of acupuncture in treatment of pregnancy-related symptoms: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2024, 44(1): 16-26.
[2]	ZHOU Xianshi, ZHONG Minlin, XI Xiaotu, LI Jun, TANG Guanghua. Efficacy and safety of Chinese herbal medicine as adjunctive therapy in sepsis patients with bloodstream infection: a propensity-matched analysis [J]. Journal of Traditional Chinese Medicine, 2024, 44(1): 197-204.
[3]	REN Ping, WANG Quanwu, BAI Wei, SUN Miao, LIU Zheling, GAO Ming, WANG Liang, PENG Bo, XU Liguang. Identifying the effective combination of acupuncture and traditional Chinese medicinal herbs for postmenopausal osteoporosis therapy through studies of their molecular regulation of bone homeostasis [J]. Journal of Traditional Chinese Medicine, 2024, 44(1): 212-219.
[4]	WANG Jiabao, ZHANG Lishuang, NIU Baihan, YU Yajun, YANG Fengwen, MIAO Lin, CHAI Lijuan, DING Xinya, SUN Yingjie, WANG Yujing, WANG Lin, ZHANG Han, WANG Yi, LI Lin. Efficacy and safety of Weichang’ an pill (胃肠安丸) combined with Western Medicine on gastrointestinal diseases: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(6): 1057-1067.
[5]	FAN Rong, HE Haoyu, TANG Tao, CUI Hanjin. Long-term effects of Qingfei Paidu decoction (清肺排毒汤) in patients with coronavirus disease 2019 acute pneumonia after treatment: a protocol for systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(6): 1068-1071.
[6]	MEI Pingping, FENG Wenzhe, SHI Peng, ZHANG Wenxiu, ZHUANG Yu. Clinical research progress in Traditional Chinese Medicine in treating wound healing after anal fistula surgery [J]. Journal of Traditional Chinese Medicine, 2023, 43(5): 1047-1054.
[7]	ZHAO HuiYan, JUN Purumea, LEE Chaewon, HAN Chang-Hyun. Acupoint catgut embedding for simple obesity in animal studies: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(5): 860-867.
[8]	SUN Wu, ZHAO Yuwei, LIAO Liang, ZHAO Zhonghui, CHEN Shiqi, YAN Xiaoling, WANG Xueyao, CHAO Guojun, ZHOU Jian. Effectiveness and safety of Xuebijing injection for patients with coronavirus disease 2019: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(4): 631-639.
[9]	MENG Xiangran, CAO Xue, SUN Minglin, AI Yanke, HE Liyun, LIU Jia. Effectiveness and safety of Angong Niuhuang pill (安宫牛黄丸) in treatment of acute stroke: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(4): 650-660.
[10]	LUO Xin, XIE Jing, HUANG Li, GAN Wenfan, CHEN Ming. Efficacy and safety of activating blood circulation and removing blood stasis of Traditional Chinese Medicine for managing renal fibrosis in patients with chronic kidney disease: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(3): 429-440.
[11]	MA Fangfang, ZHANG Hewei, LI Bingxue, CHENG Peiyu, YU Mingwei, WANG Xiaomin. Acupuncture and moxibustion for malignant tumor patients with psychological symptoms of insomnia, anxiety and depression: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(3): 441-456.
[12]	LIU Xueling, MA Kun, TAO Wenhua, XU Zhongkun, LIU Gang, HU Chunyan, MAO Weiwei, GU Chang, GUO Qi. Natural products for treatment of premature ovarian failure: a narrative review [J]. Journal of Traditional Chinese Medicine, 2023, 43(3): 606-617.
[13]	GUO Wen, LI Xuanlin, ZHAO Hulei, LEI Siyuan, XIE Yang, LI Jiansheng. Effectiveness of Chinese herbal medicine combined with conventional medicine on acute exacerbation of chronic obstructive pulmonary disease: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(2): 212-220.
[14]	ZHANG Junli, HE Ying, ZHANG Xia, FU Hongfang, HU Xiaoyu. Fuzheng Huayu preparation (扶正化瘀胶囊/片) combined with tenofovir disoproxil fumarate on hepatitis B: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(2): 221-230.
[15]	LI Yingshuai, LI Yan. Progress in the study of Yang-deficiency constitution in terms of Traditional Chinese Medicine: a narrative review [J]. Journal of Traditional Chinese Medicine, 2023, 43(2): 409-416.

Home

Online First

Author Center

Reviewer Center

Issues

Announcement

About Us